Last updated: February 14, 2026
What Is NDC 64980-0448?
NDC 64980-0448 is a prescription drug identified by the National Drug Code (NDC) as a product within the pharmaceutical market. Based on available databases, this NDC corresponds to Bupivacaine (brand or generic), a local anesthetic used for surgical procedures, labor, and postoperative pain management.
Market Overview:
Product Specifications and Indications
- Active Ingredient: Bupivacaine
- Application: Local anesthesia in surgical, obstetric, or pain management procedures
- Formulation: Typically as a solution for infiltration or nerve block
- Administration Route: Intravenous, epidural, or infiltration
Market Size and Demand Drivers
- The global local anesthetics market was valued at approximately USD 1.4 billion in 2022[1].
- The U.S. pharmaceuticals segment accounts for roughly 45% of this market, with a steady compound annual growth rate (CAGR) of 4% projected through 2027[2].
- Bupivacaine remains a leading product due to its efficacy in epidural labor analgesia and surgical anesthesia.
Competitive Landscape
- Major competitors include marcas like Sensorcaine, Marcaine, and their generics.
- The market entry of generic Bupivacaine products has exerted downward pricing pressure.
- New formulations with extended-release capabilities are emerging, potentially affecting market share dynamics.
Pricing Trends and Projections
Historical Pricing Data
- Average Wholesale Price (AWP): As of 2021-2022, AWP for a 50 mL vial of Bupivacaine ranged from USD 25 to USD 35.
- Reimbursement Rates: Reimbursement through Medicare and private insurers usually ranges from USD 60 to USD 100 per vial depending on the setting and contractual arrangements.
- Generic Price Trends: Prices have decreased by approximately 10-15% annually since 2018 due to increased competition.
Current Pricing
- 2022-2023: Estimated AWP for NDC 64980-0448 ranged around USD 20-30 per vial.
- Market Adjustments: Supply chain disruptions and regulatory changes could influence pricing variability.
Future Price Projections (Next 3-5 Years)
- Price Decreases: Anticipate further reductions due to generic competition, with projected AWP declining by 3-5% annually.
- Premium Formulations: Extended-release or liposomal Bupivacaine could command premiums of 15-25% over standard products but are not represented by this specific NDC.
- Regulatory Impact: Changes in FDA policies, such as biosimilar and generic approval pathways, may accelerate price erosion.
Key Factors Influencing Future Prices
- Regulatory Approvals: Introduction of biosimilars or new formulations could affect market share.
- Patent Expirations: While Bupivacaine itself is off-patent, patent protections on delivery devices or formulations may influence pricing.
- Supply Chain Dynamics: Manufacturing costs and raw material availability, especially post-pandemic.
- Reimbursement Environment: Coverage policies by CMS and private insurers influence net prices.
- Healthcare Policy: Moves toward value-based pricing may pressure list prices further.
Potential Market Changes
- The advent of alternative anesthetic agents or novel drug delivery systems could shift demand.
- Adoption of multi-modal analgesia protocols might reduce per-procedure usage.
- Increased use in outpatient and ambulatory surgical centers encourages larger volume but at lower margins.
Summary of Price Outlook (2023-2028)
| Year |
Expected AWP Range |
Notes |
| 2023 |
USD 20-30 |
Current market prices, slight downward trend |
| 2024 |
USD 19-28 |
Continued generic competition, minor reductions |
| 2025 |
USD 18-26 |
Market saturation, new formulations impact |
| 2026 |
USD 17-25 |
Possible entry of biosimilars or generics |
| 2027 |
USD 16-24 |
Further price compression |
Note: Market dynamics and regulatory shifts could accelerate or slow this trajectory.
Key Takeaways
- NDC 64980-0448 corresponds to Bupivacaine, a widely used local anesthetic.
- The U.S. market for Bupivacaine is valued at roughly USD 600 million annually, with continued growth driven by procedural volume.
- Prices have declined steadily due to generics, with a forecast of further reductions over the next few years.
- Supply chain issues and regulatory policy developments will influence market prices and availability.
- Broader medical trends favor increased outpatient procedures, which could sustain demand despite pricing pressures.
FAQs
Q1: Will the price of NDC 64980-0448 decrease further in the next five years?
Yes, primarily due to the proliferation of generic products and market saturation, expect a continued downward trend of 3-5% annually.
Q2: What factors could stabilize or increase the price of Bupivacaine?
Introduction of innovative formulations, shortages in raw materials, or regulatory barriers delaying generic entry.
Q3: How do reimbursement policies affect the net price for hospitals and clinics?
Payments often lag or are reduced due to negotiations and insurer policies, influencing the overall profitability and markets' willingness to pay.
Q4: Are new formulations impacting the traditional Bupivacaine market?
Yes, extended-release formulations, which can command higher prices, are gaining market share but are not directly comparable to standard solutions represented by this NDC.
Q5: What are the primary competitors for NDC 64980-0448?
Brands like Marcaine and Sensorcaine, along with numerous generic equivalents, dominate the market landscape.
Sources:
[1] Market Research Future. Local Anesthetics Market Report, 2022.
[2] IQVIA. U.S. Pharmaceutical Market Analysis, 2022.
